Low‐dose alemtuzumab‐associated immune thrombocytopenia in chronic lymphocytic leukemia

Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Francesco Rodeghiero(Ospedale San Bortolo), Francesca Guidotti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Carlo Visco(University of Verona), Alfonso Piciocchi(Fondazione Gimema Onlus), Francesca Binda(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Anna Ines Gregorini(University of Milan), Francesco Maura(Memorial Sloan Kettering Cancer Center), Giuseppe Gritti(Ospedale Papa Giovanni XXIII)
American Journal of Hematology
May 21, 2012
10.1002/ajh.23268
Cited by 18

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
|Blood|2008|2.6k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
|Cell|2018|565
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition
|Nature Genetics|2020|485